Meeting
2018 ASCO Quality Care Symposium
Impact of novel chronic lymphocytic leukemia drugs on public spending.
Authors
Elena Mow
Provincial Drug Reimbursement Programs, Cancer Care Ontario, Toronto, ON, Canada
Elena Mow, James Keech, Rohini Naipaul, Jaclyn Marie Beca, Scott Gavura, C. Tom Kouroukis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Big Data Studies; Projects Relating to Equity, Value, and Policy
Track
Projects Relating to Equity, Value and Policy,Big Data Studies
Sub Track
Measuring Value and Costs
Citation
J Clin Oncol 36, 2018 (suppl 30; abstr 103)
DOI
10.1200/JCO.2018.36.30_suppl.103
Abstract #
103
Poster Bd #
K10
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Quality Care Symposium
What are the health care costs for chronic lymphocytic leukemia?
First Author: Matthew J. Matasar
Poster
2018 ASCO Annual Meeting
Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia.
First Author: Von Tresckow Julia
Poster
2016 ASCO Annual Meeting
Evaluation of the novel Bruton′s tyrosine kinase (BTK) inhibitor GDC-0853 in chronic lymphocytic leukemia (CLL) with wild type or C481S mutated BTK.
First Author: Sean David Reiff
Poster
2023 ASCO Annual Meeting
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
First Author: Christopher Flowers